Emergent complications following donepezil switchover to galantamine in three cases of dementia with lewy bodies

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 17, Issue 4, 2005, Pages 552-555

  Bhanji, Nadeem H ^a   Gauthier, Serge ^b  

^a Allan Memorial Institute   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; QUETIAPINE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CHOLINESTERASE INHIBITION; DELIRIUM; DELUSION; DEMENTIA; DEMENTIA WITH LEWY BODY; DISEASE COURSE; DRUG DISCONTINUATION SYNDROME; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; EVIDENCE BASED MEDICINE; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HUMAN; INSOMNIA; LEWY BODY; MALE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SIDE EFFECT; TREATMENT OUTCOME; VISUAL HALLUCINATION;

EID: 29044441412     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.17.4.552     Document Type: Article

References (15)

1. Holmes C, Cairns N, Lantos P, et al: Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 2001; 174:45-51
2. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report on the consortium on DLB international workshop. Neurology 1996; 47:1113-1124
3. McKeith I, Del Ser T, Spano P, et al: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036
4. National Institute for Clinical Excellence (NICE): Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease (number 19, 19 Jan 2001). Available at: http://www.nice.org.uk. Accessed July 22, 2002
5. Grace J, Daniel S, Stevens T, et al: Long-term use of rivastigmine in patients with dementia with Lewy bodies: an open-label study. Int Psychogeriatr 2001; 13:199-205
6. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48:S10-S16
7. Perry EK, Haroutinian V, Davis KL: Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994; 5:747-749
8. Shiozaki K, Iseki E, Uchiyama H, et al: Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J Neurol Neurosurg Psychiatr 1999; 67:209-213
9. Ballard CG: Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47:64-70
10. Auriacombe S, Pere J-J, Loria-Kanz Y, et al: Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002; 3:129-138
11. Taylor AM, Hoehns JD, Anderson DM, Tobert DG: Fatal aspiration pneumonia during transition from donepezil to rivastigmine. Ann Pharmacother 2002; 36:1550-1153
12. Wilkinson L, Daniel S, Newby J, et al. Donepezil treatment and withdrawal in patients with dementia with Lewy bodies (DLB) and patients with Parkinson's disease + DLB: Poster Presentation (number 288), International Conference on Alzheimer's disease and Related Disorders. Stockholm. 20-25 July 2002
13. Singh S, Dudley C: Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 2003; 18:282-284
14. Minett TSC, Thomas A, Wilkinson LM, et al: What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18:988-993
15. Subbiah P, Schwam EM: Unsafe prescription medication switching recommendations. Clin Ther 2001; 23:2050-2202